Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

Inclusion criteria: * All subjects: • Female subjects must be of non-child bearing potential OR use an effective method of contraception and sexually active males must use a condom during intercourse while taking the drug and for 5 half-lives after stopping treatment * Subjects with hepatic impairment: * Subjects must have either mild, moderate or severe hepatic impairment Exclusion criteria: * All subjects * Hepatic impairment due to non-liver disease * Use of other investigational drugs at time of enrollment * History of malignancy of any organ system * Donation or loss of 400 mL or more of blood or plasma within 8 weeks prior to initial dosing * Hemoglobin levels below 10.0 g/dL at screening or baseline * Subjects with hepatic impairment: * Presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk * Treatment with any cytostatic drug, vasodilator, autonomic alpha blocker or B2 agonist * Any surgical or medical condition other than hepatic impairment which might significantly alter the distribution or excretion of drugs Other protocol-defined inclusion/exclusion criteria may apply.